Shanghai Labway Clinical Laboratory Co., Ltd Stock price

Equities

301060

CNE100004RG8

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
12 CNY +3.36% Intraday chart for Shanghai Labway Clinical Laboratory Co., Ltd -14.59% -9.71%
Sales 2021 1.78B 246M Sales 2022 4.2B 582M Capitalization 7.85B 1.09B
Net income 2021 204M 28.26M Net income 2022 617M 85.48M EV / Sales 2021 7.42 x
Net cash position 2021 707M 97.97M Net cash position 2022 421M 58.35M EV / Sales 2022 1.77 x
P/E ratio 2021
60.1 x
P/E ratio 2022
12.7 x
Employees 1,878
Yield 2021
0.86%
Yield 2022
1.53%
Free-Float 32.29%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023. CI
Shanghai Labway Clinical Laboratory Co., Ltd announces an Equity Buyback for CNY 30 million worth of its shares. CI
Shanghai Labway Clinical Laboratory Co., Ltd authorizes a Buyback Plan. CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2023. CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Labway Clinical Laboratory to Buy Enterprise Management Firm For 283 Million Yuan MT
Shanghai Labway Clinical Laboratory Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023 CI
Shanghai Labway Clinical Laboratory Co., Ltd Approves Cash Dividend for 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd Proposes Final Cash Dividend for the Year 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd cancelled the transaction announced on September 1, 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
As China seeks to live with the virus, COVID-control industries face decline RE
Chinese COVID testing firms report big profits as virus fight intensifies RE
More news
1 day+3.36%
1 week-14.59%
Current month+18.46%
1 month+22.32%
3 months-8.68%
6 months-16.61%
Current year-9.71%
More quotes
1 week
11.36
Extreme 11.36
13.08
1 month
9.65
Extreme 9.65
14.77
Current year
7.34
Extreme 7.34
14.77
1 year
7.34
Extreme 7.34
27.26
3 years
7.34
Extreme 7.34
61.20
5 years
7.34
Extreme 7.34
61.20
10 years
7.34
Extreme 7.34
61.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 15-08-19
Director of Finance/CFO 54 22-07-21
Director/Board Member 64 21-12-16
Members of the board TitleAgeSince
Director/Board Member 42 21-12-16
Director/Board Member 61 15-08-19
Chief Executive Officer 56 15-08-19
More insiders
Date Price Change Volume
24-03-28 12 +3.36% 12,871,570
24-03-27 11.61 -2.27% 17,659,530
24-03-26 11.88 -1.57% 12,607,730
24-03-25 12.07 -8.91% 20,446,160
24-03-22 13.25 -5.69% 28,671,280

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
Shanghai Labway Clinical Laboratory Co Ltd is a company providing overall solutions for the inspection and diagnosis industry. The Company's businesses include medical testing and pathological diagnosis services and the sales of in vitro diagnosis product. The medical examination and pathological diagnosis services include pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination and physical and chemical examination. The in vitro diagnostic products sales include in vitro diagnostic instruments, reagents and related accessories and consumables.
More about the company
  1. Stock
  2. Equities
  3. Stock Shanghai Labway Clinical Laboratory Co., Ltd - Shenzhen S.E.